European Heart Journal · 2018 · 56 citations · 21 references
PharmacyCardiologyGeriatric MedicineCardiovascular PharmacotherapyGeriatric PharmacotherapySurvival AnalysisCardiac MedicationsCardiovascular DiseaseCardiovascular Pharmacotherapy In Older AdultsHeart FailureHeart Failure PharmacotherapyMortality ModelingCox RegressionHazard Ratio ModelingHeart Failure EpidemiologyMatched Cohort DesignPropensity Score AdjustmentRenin-angiotensin System InhibitorsRenin-angiotensin-aldosterone System InhibitionRenin-angiotensin-aldosterone System Inhibitors
Aims: In heart failure with reduced ejection fraction (HFrEF), renin-angiotensin system inhibitors (RASi) improve morbidity and mortality. However, patients aged >80 years constituted a small minority in trials. We assessed the association between RASi use and mortality/morbidity in HFrEF patients aged >80 years. Methods and results: We included patients with ejection fraction <40% and age >80 years from the Swedish Heart Failure Registry. Propensity scores for RASi use were calculated from 37 variables. Cox regression models for RASi vs. non-RASi with all-cause mortality and all-cause mortality/heart failure (HF) hospitalization as outcomes were fitted in a 1:1 propensity-score-matched cohort. To assess consistency, the same analyses were performed in a 'positive control' cohort aged ≤80 years. Of 6710 patients [median age (interquartile range) 85 (82-87) years; 38% women], 5384 (80%) received RASi. Propensity-score matching yielded 2416 patients, [age 86 (83-91) years]. RASi use was associated with hazard ratio (HR) (95% confidence interval) 0.78 (0.72-0.86) for all-cause mortality and 0.86 (0.79-0.94) for all-cause mortality/HF hospitalization. In positive control patients aged ≤80 years (17 842 patients in the overall cohort, 2126 after matching), HR for all-cause mortality was 0.81 (0.71-0.91), whereas it was 0.85 (0.76-0.94) for all-cause mortality/HF hospitalization. Conclusion: In HFrEF patients with age >80 years, RASi were relatively underused compared with in younger patients, despite similar association with reduced morbidity and mortality and no apparent association with risk of syncope-related hospitalization. These results may be interpreted as hypothesis generating for randomized clinical trials on RASi in this elderly HFrEF subpopulation.
21
John G.F. Cleland, Andrew J.S. Coats, Ewa A. Jankowska et al. · PubMed · 2021 · 19.5K citations
External review and validation of the Swedish national inpatient register
Jonas F. Ludvigsson, Eva Andersson, Anders Ekbom et al. · BMC Public Health · 2011 · 5.1K citations · Full text